Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases.

Yokoyama Y, Lew ED, Seelige R, Tindall EA, Walsh C, Fagan PC, Lee JY, Nevarez R, Oh J, Tucker KD, Chen M, Diliberto A, Vaaler H, Smith KM, Albert A, Li G, Bui JD.

Cancer Res. 2019 Feb 5. pii: canres.2022.2018. doi: 10.1158/0008-5472.CAN-18-2022. [Epub ahead of print]

PMID:
30723115
2.

Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas.

Gross ETE, Peinado CD, Jung Y, Han S, Liu B, Santosa EK, Bui JD.

Oncoimmunology. 2018 Oct 31;8(1):e1404212. doi: 10.1080/2162402X.2017.1404212. eCollection 2019.

PMID:
30546937
3.

Siglec-7 engagement by GBS β-protein suppresses pyroptotic cell death of natural killer cells.

Fong JJ, Tsai CM, Saha S, Nizet V, Varki A, Bui JD.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10410-10415. doi: 10.1073/pnas.1804108115. Epub 2018 Sep 25.

PMID:
30254166
4.

Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection.

Seelige R, Saddawi-Konefka R, Adams NM, Picarda G, Sun JC, Benedict CA, Bui JD.

Sci Rep. 2018 Sep 12;8(1):13670. doi: 10.1038/s41598-018-32011-2.

5.

LGI1 and CASPR2 neurological autoimmunity in children.

López-Chiriboga AS, Klein C, Zekeridou A, McKeon A, Dubey D, Flanagan EP, Lennon VA, Tillema JM, Wirrell EC, Patterson MC, Gadoth A, Aaen JG, Brenton JN, Bui JD, Moen A, Otten C, Piquet A, Pittock SJ.

Ann Neurol. 2018 Sep;84(3):473-480. doi: 10.1002/ana.25310.

PMID:
30076629
6.

Cyclic hypersomnolence with symptoms of narcolepsy with cataplexy: An unusual presentation of probable immune-mediated encephalitis.

Willenberg R, Bui JD.

eNeurologicalSci. 2018 Jan 28;10:26-27. doi: 10.1016/j.ensci.2018.01.003. eCollection 2018 Mar.

7.

Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance.

Klann JE, Kim SH, Remedios KA, He Z, Metz PJ, Lopez J, Tysl T, Olvera JG, Ablack JN, Cantor JM, Boland BS, Yeo G, Zheng Y, Lu LF, Bui JD, Ginsberg MH, Petrich BG, Chang JT.

J Immunol. 2018 Jun 15;200(12):4012-4023. doi: 10.4049/jimmunol.1800112. Epub 2018 Apr 27.

PMID:
29703862
8.

Isoflurane Impacts Murine Melanoma Growth in a Sex-Specific, Immune-Dependent Manner: A Brief Report.

Meier A, Gross ETE, Schilling JM, Seelige R, Jung Y, Santosa E, Searles S, Lin T, Tu XM, Patel HH, Bui JD.

Anesth Analg. 2018 Jun;126(6):1910-1913. doi: 10.1213/ANE.0000000000002902.

PMID:
29570154
9.

Cell-cell fusion as a mechanism of DNA exchange in cancer.

Searles SC, Santosa EK, Bui JD.

Oncotarget. 2017 Dec 27;9(5):6156-6173. doi: 10.18632/oncotarget.23715. eCollection 2018 Jan 19.

10.

The Next Frontier: Head and Neck Cancer Immunoprevention.

Gutkind JS, Bui JD.

Cancer Prev Res (Phila). 2017 Dec;10(12):681-683. doi: 10.1158/1940-6207.CAPR-17-0331. Epub 2017 Nov 14.

11.

Innate sensing of cancer's non-immunologic hallmarks.

Seelige R, Searles S, Bui JD.

Curr Opin Immunol. 2018 Feb;50:1-8. doi: 10.1016/j.coi.2017.09.005. Epub 2017 Oct 12. Review.

12.

Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification.

Widjaja CE, Olvera JG, Metz PJ, Phan AT, Savas JN, de Bruin G, Leestemaker Y, Berkers CR, de Jong A, Florea BI, Fisch K, Lopez J, Kim SH, Garcia DA, Searles S, Bui JD, Chang AN, Yates JR 3rd, Goldrath AW, Overkleeft HS, Ovaa H, Chang JT.

J Clin Invest. 2017 Oct 2;127(10):3609-3623. doi: 10.1172/JCI90895. Epub 2017 Aug 28.

13.

Mechanisms regulating immune surveillance of cellular stress in cancer.

Seelige R, Searles S, Bui JD.

Cell Mol Life Sci. 2018 Jan;75(2):225-240. doi: 10.1007/s00018-017-2597-7. Epub 2017 Jul 25. Review.

PMID:
28744671
14.

Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Gross ET, Han S, Vemu P, Peinado CD, Marsala M, Ellies LG, Bui JD.

Oncoimmunology. 2016 Dec 14;6(2):e1268310. doi: 10.1080/2162402X.2016.1268310. eCollection 2017.

15.

Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD.

Biol Blood Marrow Transplant. 2017 Apr;23(4):625-634. doi: 10.1016/j.bbmt.2017.01.069. Epub 2017 Jan 16.

16.

The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance.

Seelige R, Washington A Jr, Bui JD.

Cytokine. 2017 Mar;91:10-12. doi: 10.1016/j.cyto.2016.11.017. Epub 2016 Dec 9. Review.

17.

Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance.

Saddawi-Konefka R, Seelige R, Gross ET, Levy E, Searles SC, Washington A Jr, Santosa EK, Liu B, O'Sullivan TE, Harismendy O, Bui JD.

Cell Rep. 2016 Aug 30;16(9):2348-58. doi: 10.1016/j.celrep.2016.07.075. Epub 2016 Aug 18.

18.

Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.

Doedens AL, Rubinstein MP, Gross ET, Best JA, Craig DH, Baker MK, Cole DJ, Bui JD, Goldrath AW.

Cancer Immunol Res. 2016 Sep 2;4(9):799-811. doi: 10.1158/2326-6066.CIR-15-0178. Epub 2016 Aug 2.

19.

Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.

Banno A, Garcia DA, van Baarsel ED, Metz PJ, Fisch K, Widjaja CE, Kim SH, Lopez J, Chang AN, Geurink PP, Florea BI, Overkleeft HS, Ovaa H, Bui JD, Yang J, Chang JT.

Oncotarget. 2016 Apr 19;7(16):21527-41. doi: 10.18632/oncotarget.7596.

20.

Tumor-expressed IL-17D recruits NK cells to reject tumors.

Saddawi-Konefka R, O'Sullivan T, Gross ET, Washington A Jr, Bui JD.

Oncoimmunology. 2015 Jan 7;3(12):e954853. eCollection 2014 Dec.

21.

Effect of cell density and HLA-DR incompatibility on T-cell proliferation and forkhead box P3 expression in human mixed lymphocyte reaction.

Song EY, Han S, Yang B, Morris GP, Bui JD.

Transplant Proc. 2015 Apr;47(3):763-9. doi: 10.1016/j.transproceed.2015.02.005.

PMID:
25891727
22.

Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency.

Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT.

J Immunol. 2015 Mar 15;194(6):2551-60. doi: 10.4049/jimmunol.1401463. Epub 2015 Feb 9.

23.

Drak2 is not required for tumor surveillance and suppression.

Edwards BA, Harris TL, Floersh H, Lukens JR, Zaki MH, Vogel P, Kanneganti TD, Bui JD, McGargill MA.

Int Immunol. 2015 Mar;27(3):161-6. doi: 10.1093/intimm/dxu146. Epub 2015 Jan 7.

24.

uPAR induces expression of transforming growth factor β and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.

Hu J, Jo M, Eastman BM, Gilder AS, Bui JD, Gonias SL.

Am J Pathol. 2014 Dec;184(12):3384-93. doi: 10.1016/j.ajpath.2014.08.003. Epub 2014 Oct 11.

25.

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Läubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui JD, Varki A.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211-6. doi: 10.1073/pnas.1409580111. Epub 2014 Sep 15.

26.

Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.

O'Sullivan T, Saddawi-Konefka R, Gross E, Tran M, Mayfield SP, Ikeda H, Bui JD.

Cell Rep. 2014 May 22;7(4):989-98. doi: 10.1016/j.celrep.2014.03.073. Epub 2014 May 1.

27.

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.

Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5998-6003. doi: 10.1073/pnas.1209067111. Epub 2014 Apr 7.

28.

Cancer immunosurveillance and immunoediting by natural killer cells.

Gross E, Sunwoo JB, Bui JD.

Cancer J. 2013 Nov-Dec;19(6):483-9. doi: 10.1097/PPO.0000000000000005. Review.

PMID:
24270347
29.

Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor.

Shin JH, Zhang L, Murillo-Sauca O, Kim J, Kohrt HE, Bui JD, Sunwoo JB.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12391-6. doi: 10.1073/pnas.1302856110. Epub 2013 Jul 8.

30.

Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: effect on spinally grafted human neural precursor survival.

Sevc J, Goldberg D, van Gorp S, Leerink M, Juhas S, Juhasova J, Marsala S, Hruska-Plochan M, Hefferan MP, Motlik J, Rypacek F, Machova L, Kakinohana O, Santucci C, Johe K, Lukacova N, Yamada K, Bui JD, Marsala M.

Exp Neurol. 2013 Oct;248:85-99. doi: 10.1016/j.expneurol.2013.05.017. Epub 2013 Jun 5.

PMID:
23748136
31.

The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy.

Peinado C, Kang X, Hardamon C, Arora S, Mah S, Zhang H, Ngolab J, Bui JD.

Immunology. 2013 Jun;139(2):265-74. doi: 10.1111/imm.12080.

32.

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD.

J Exp Med. 2012 Sep 24;209(10):1869-82. Epub 2012 Aug 27.

33.

Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer.

Kreisel D, Gelman AE, Higashikubo R, Lin X, Vikis HG, White JM, Toth KA, Deshpande C, Carreno BM, You M, Taffner SM, Yokoyama WM, Bui JD, Schreiber RD, Krupnick AS.

Cancer Res. 2012 Sep 1;72(17):4311-7. Epub 2012 Jun 29.

34.

A dual function of NKG2D ligands in NK-cell activation.

Cheney EE, Wise EL, Bui JD, Schreiber RD, Carayannopoulos LN, Spitzer D, Zafirova B, Polic B, Shaw AS, Markiewicz MA.

Eur J Immunol. 2012 Sep;42(9):2452-8. doi: 10.1002/eji.201141849. Epub 2012 Jul 27.

35.

The clinical implications of antitumor immunity in head and neck cancer.

Allen CT, Judd NP, Bui JD, Uppaluri R.

Laryngoscope. 2012 Jan;122(1):144-57. doi: 10.1002/lary.21913. Review.

PMID:
22183634
36.

ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.

Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R.

Cancer Res. 2012 Jan 1;72(1):365-74. doi: 10.1158/0008-5472.CAN-11-1831. Epub 2011 Nov 15.

37.

Cancer immunoediting of the NK group 2D ligand H60a.

O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD.

J Immunol. 2011 Oct 1;187(7):3538-45. doi: 10.4049/jimmunol.1100413. Epub 2011 Aug 29.

38.

Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.

Yadav D, Ngolab J, Dang N, Bui JD.

Immunology. 2011 Jun;133(2):197-205. doi: 10.1111/j.1365-2567.2011.03427.x. Epub 2011 Mar 25.

39.

Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression.

Zhang H, Hardamon C, Sagoe B, Ngolab J, Bui JD.

Mol Immunol. 2011 Jan;48(4):539-45. doi: 10.1016/j.molimm.2010.10.015. Epub 2010 Nov 19.

40.

The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth.

Büchau AS, Morizane S, Trowbridge J, Schauber J, Kotol P, Bui JD, Gallo RL.

J Immunol. 2010 Jan 1;184(1):369-78. doi: 10.4049/jimmunol.0902110. Epub 2009 Nov 30.

41.

Magnetic resonance microscopy of mammalian neurons.

Flint JJ, Lee CH, Hansen B, Fey M, Schmidig D, Bui JD, King MA, Vestergaard-Poulsen P, Blackband SJ.

Neuroimage. 2009 Jul 15;46(4):1037-40. doi: 10.1016/j.neuroimage.2009.03.009. Epub 2009 Mar 12.

42.

Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA.

Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui JD.

J Immunol. 2009 Jan 1;182(1):39-43.

43.

Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody.

Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B, Gerard C, Hancock WW, Schreiber RD.

Transplantation. 2008 Jul 15;86(1):137-47. doi: 10.1097/TP.0b013e31817b8e4b.

44.

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

Bui JD, Schreiber RD.

Curr Opin Immunol. 2007 Apr;19(2):203-8. Epub 2007 Feb 9. Review.

PMID:
17292599
45.

Non-invasive evaluation of alginate/poly-l-lysine/alginate microcapsules by magnetic resonance microscopy.

Constantinidis I, Grant SC, Celper S, Gauffin-Holmberg I, Agering K, Oca-Cossio JA, Bui JD, Flint J, Hamaty C, Simpson NE, Blackband SJ.

Biomaterials. 2007 May;28(15):2438-45. Epub 2007 Jan 8.

46.
47.

IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.

Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD.

J Immunol. 2006 Jan 15;176(2):905-13.

48.

Central neurogenic hyperventilation: a case report and discussion of pathophysiology.

Tarulli AW, Lim C, Bui JD, Saper CB, Alexander MP.

Arch Neurol. 2005 Oct;62(10):1632-4.

PMID:
16216951
49.

Active Ca2+/calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling.

McGargill MA, Sharp LL, Bui JD, Hedrick SM, Calbo S.

J Immunol. 2005 Jul 15;175(2):656-64.

50.

A critical function for type I interferons in cancer immunoediting.

Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD.

Nat Immunol. 2005 Jul;6(7):722-9. Epub 2005 Jun 12. Erratum in: Nat Immunol. 2005 Aug;6(8):852.

PMID:
15951814

Supplemental Content

Support Center